Heparin in acute stroke
In the International stroke trial the group that received heparin had a significant 0.9% reduction in risk of recurrent stroke within 14 days. This was however counter balanced by a significant 0.8% increase in haemorrhagic stroke.
Trials involving low-molecular weight heparins, nadroparin and danaparoid have not convincingly shown benefit of these therapies.
Related pages
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page